24 results about "Neutral lipid" patented technology

The invention discloses a structure annotation method for analyzing positions sn-and C = C of lipid based on liquid chromatography-organic matter ion electron collision excitation mass spectrometry. According to the method, a proper amount of 0.1 mM sodium acetate is added during lipid redissolution, so that polar lipid and neutral lipid are analyzed at the same time through one-time sample introduction. Meanwhile, a method for automatically annotating the complex organic matter ion electron collision excitation mass spectrum is developed, and the method comprises the steps of (1) extracting mass spectrum information in original data, (2) identifying lipid subclasses, (3) matching lipid total composition, (4) pairing sn-position, (5) positioning C = C position, and (6) determining annotation level. For 34 lipid standard substances in serum, the annotation accuracy rates of the annotation method on sn-and C = C isomer levels are 100% and 82.3% respectively. A total of 1312 sn-isomers and 1033 C = C isomers are annotated from mixed plasma samples of healthy people and patients with mild cognitive impairment of Alzheimer's disease. In a word, the lipid fine structure analysis method developed by the invention has the characteristics of simple pretreatment, high coverage and efficient annotation of the lipid fine structure.

The invention relates to HIF-1alpha siRNA lipid nanoparticles and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: S1, dissolving ionizable lipid, neutral lipid, cholesterol and pegylated lipid in an organic solvent to obtain an oil phase; the method comprises the following steps: dissolving HIF-1alpha siRNA in a first buffer solution to obtain a water phase; s2, mixing the oil phase and the water phase by adopting a micro-fluidic technology, diluting with a second buffer solution, removing the organic solvent, and concentrating to obtain the HIF-1alpha siRNA lipid nanoparticles, the targeted delivery of the HIF-1alpha siRNA is realized, so that the HIF-1alpha siRNA is effectively delivered to the rheumatoid arthritis diseased region through the delivery system to play a therapeutic role.

The present disclosure provides a lipid compound, which can be used in combination with other lipid components, such as neutral lipids, cholesterol, and polymer-lipid conjugates, to form lipid nanoparticles for delivery of therapeutic agents (e.g. nucleic acid molecules) for therapeutic or prophylactic purposes, comprising vaccination. Also provided herein is a lipid nanoparticle composition comprising the lipid compound.

Provided herein is a lipid nanoparticle comprising an encapsulated oligonucleotide molecule, wherein the oligonucleotide molecule is single-stranded or double-stranded and has a length of between 5 and 500 nucleotides; and 20 to 70 mol % of a neutral lipid content relative to total lipid present in the lipid nanoparticle, an ionizable lipid; a sterol; and optionally a hydrophilic polymer-lipid conjugate.

A lipid nanoparticle composition targeting to antigen-presenting cells (APCs), comprising: at least a therapeutic agent, at least a cationic or ionizable cationic lipid, at least a neutral lipid, at least a steroid or steroid analogue, at least a PEGylated lipid, and atleast a phosphatidylglycerol.

The present disclosure provides a lipid nanoparticle, the lipid nanoparticle comprises a cationic lipid, a neutral lipid, a PEG lipid and an active pharmaceutical ingredient, the cationic lipid comprises DOTAP, and the active pharmaceutical ingredient comprises one or more of nucleoside, a nucleoside analogue or a compound with a phosphate group. The lipid nanoparticles are high in stability and bioavailability, and the effect of the lipid nanoparticles is better than that of a drug monomer.

Provided is a lipid nanoparticle comprising capped mRNA bearing one or more ribose modifications, and 20 to 70 mol % of a neutral lipid, an ionizable lipid; and a sterol and optionally a hydrophilic polymer-lipid conjugate, the lipid nanoparticles exhibiting at least a 10% increase in extrahepatic protein expression of the mRNA in vivo, as measured in one or more extrahepatic organs or tissues. In some examples, the mRNA comprises a 5' cap having an N7-methylated guanosine at a position 0, and a nucleoside at a position 1 linked to the N7-methylated guanosine by a 5' to 5' bridge, wherein the N7-methylated guanosine has a modification at a 3' carbon of its ribose and / or the nucleoside at the position 1 has a modification at a 2' carbon of its ribose.

This disclosure provides unshielded lipid nanoparticles and a method for producing such unshielded lipid nanoparticles, thereby overcoming the challenge of preparing particles without causing their aggregation. The lipid nanoparticles comprise nucleic acid cargo molecules; sterols or derivatives thereof present in an amount of at least 12% molar ratio; neutral lipids, such as phospholipids having a choline head group, in an amount of 22% to 65% molar ratio; and ionizable cationic amino lipids in an amount of 15% to 45% molar ratio; wherein the lipid nanoparticles are not sterically stabilized by a hydrophilic polymer-lipid conjugate or are unshielded, and wherein each % molar ratio is relative to the total lipids present in the lipid nanoparticles.

Compositions comprising Serenoa serrulata (saw palmetto) fruit extract, Laminaria saccharina (brown algae) extract, and Glycyrrhiza inflata root extract are effective inhibit the activity of 5-alpha Reductase; lower neutral lipid content; and reduce expression of SREBP1, FASN and ACACA, in human sebocytes. By regulating excess sebum production, compositions of the invention are useful to improve the health and appearance of skin.

The present disclosure provides a lipid nanoparticle comprising: nucleic acid cargo; ionizable lipid; non-polar, neutral lipid, such as a phospholipid; non-polar lipid, such as a glyceride; and sterol, the lipid nanoparticle being unshielded and wherein each mol% content is relative to total lipid present in the lipid nanoparticle.

Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes, including vaccination. Also provided herein are lipid nanoparticle compositions comprising said lipid compounds.

The invention relates to a process for the preparation of a composition comprising an oligosaccharide or a polysaccharide encapsulated in lipid nanoparticles, the process comprising the following steps: preparing a first solution of a lipid portion comprising a phospholipid, a neutral lipid, and a lipid sterol; preparing a second solution comprising a poly- or oligosaccharide; preparing a third solution containing a buffer; mixing the first and second solutions using a microfluidic system to obtain lipid nanoparticles encapsulating the oligosaccharide or the polysaccharide; combining the third solution with the first and second solutions. The invention also relates to a composition comprising lipid nanoparticles obtainable by the above-defined process, said composition comprising a lipid portion comprising a phospholipid, a neutral lipid compound in which a lipid chain is bound to a glycol group, and a lipid sterol; a buffer; and an oligosaccharide or polysaccharide.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Compositions comprising Serenoa serrulata (saw palmetto) fruit extract, Laminaria saccharina (brown algae) extract, and Glycyrrhiza inflata root extract are effective inhibit the activity of 5-alpha Reductase; lower neutral lipid content; and reduce expression of SREBP1, FASN and ACACA, in human sebocytes. By regulating excess sebum production, compositions of the invention are useful to improve the health and appearance of skin.

Provided herein are polyglycerol conjugated lipid compounds that can be used in combination with other lipid components, such as cationic lipids, neutral lipids, and cholesterol, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes. Also provided herein are lipid nanoparticle compositions comprising said polymer conjugated lipid compounds.

The application discloses a kind of pemetrexed liposome and its preparation method and application, it is made of including 2mg / mL~20mg / mL pemetrexed or its pharmaceutically acceptable salt, 2.2mg / mL~12mg / mL cholesterols, 6.81mg / mL~108mg / mL neutral lipid, 12mg / mL~98mg / mL cationic lipid and 0.12mg / mL~2.12mg / mL PEG-lipid.The pemetrexed liposome of the application can significantly improve the enrichment of pemetrexed drug in tumor site, thereby enhancing drug treatment effect, reducing dosing dose, reducing the toxic side effects of drug on normal tissue.And it has good stability, no obvious change in storage process nature, particle size, zeta potential and encapsulation efficiency.

The present invention is in the field of drug delivery and relates to relates to novel cationic lipids that can be used alone or in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles with oligonucleotides, to facilitate the targeted intracellular delivery of therapeutic nucleic acids.

The present document relates to lipid compounds and lipid nanoparticle compositions. In particular, it relates to lipid compounds which can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer-conjugated lipids, to form lipid nanoparticles for the delivery of therapeutic agents, such as nucleic acid molecules, for therapeutic or prophylactic purposes. The present document also provides lipid nanoparticle compositions comprising the lipid compounds.

The invention discloses a dynamic detection method for mouse liver organoid response lipid, and belongs to the technical field of biological research. Culturing the liver-like organs of the mouse to a preset number of days; randomly dividing the organs into at least three groups, and respectively treating by using a complete culture medium, a culture medium containing free fatty acid and a culture medium containing cholesterol; after the treatment is finished, sequentially carrying out bright field imaging and oil red O dyeing imaging on the same batch of organ-like samples; organ-like morphological parameters obtained by bright field images and the overall accumulation condition of neutral lipid disclosed by oil red O staining images are integrated and analyzed, and the cell growth condition of mouse liver organ-like cells and histological morphological change of the organ-like are evaluated by HE staining. Therefore, multi-dimensional and visual distinguishing and quantitative evaluation of lipid metabolism response induced by fatty acid and cholesterol are realized. According to the method, form-phenotype-molecule comprehensive evaluation is realized, and the problems that in the prior art, the information dimension is limited, and different lipid responses cannot be accurately distinguished are solved.

The invention provides a lipidosome composite adjuvant containing cyclic dinucleotide molecules, the lipidosome composite adjuvant comprises a first lipidosome, a second lipidosome and cyclic dinucleotide, and lipid components of the first lipidosome comprise neutral lipid and monophosphoryl lipid A; the lipid components of the second liposome comprise neutral lipid, cationic lipid and polyethylene glycol lipid. The phospholipid bilayer on the surface of the liposome adjuvant has good biocompatibility and cell uptake promotion effect, the phospholipid bilayer is combined with monophosphoryl lipid A and cyclic dinucleotide molecules to activate TLR4 and STING pathways at the same time, TH1 type immune response is promoted synergistically, cellular immunity is improved, and the liposome adjuvant is especially suitable for disease prevention vaccines mainly based on cellular immunity. The safety is high, and the device is suitable for multi-way inoculation of cavity mucosa, subcutaneous and intradermal / intramuscular injection and the like.

This invention provides aminolipids, lipid nanoparticles, and their uses. The aminolipids have a structure represented by general formula (I), or isomers thereof, pharmaceutically acceptable salts, prodrugs, or solvates. This invention further provides lipid nanoparticles containing these aminolipids. In this invention, an aminolipid having the structure represented by general formula (I) is used as an ionizable lipid compound and obtained LNP by self-assembling with a steroid, a neutral lipid, and a polymer-bound lipid. These LNPs improve the intracellular translational expression level of the supported nucleic acid, enhance the action of nucleic acid-LNP formulations, and provide a theoretical basis for personalized therapy with nucleic acid-LNP formulations. TIFF2026516582000075.tif28170

The present invention provides: a neutral lipid capable of suppressing the phase transition of endosomal membranes caused by phosphatidylcholine from being inhibited; and a lipid nanoparticle containing the neutral lipid. The present invention pertains to an ionic neutral lipid comprising a compound represented by general formula (I). [In formula (I), R1 is a C1-22 hydrocarbon group; three R1 groups in one molecule may be the same as or different from each other; a1 and a2 are each independently an integer of 0 to 4; b1 and b2 are 0 or 1, satisfying b1+b2=1; R2 and R3 are each independently a hydrogen atom or a C1-3 alkyl group; and R4 is an anionic group.]